Nurix director Lori Kunkel resigns; Roy Baynes named committee chair

Nurix Therapeutics, Inc.

Director Lori A. Kunkel, M.D. resigns from Board and committees effective September 1, 2025.
Resignation not due to any disagreement with company on operations, policies, or practices.
Board appoints Roy D. Baynes, MB.Bch., M.Med., Ph.D., as chair of Clinical and Commercialization Committee.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.